{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:08:43Z","timestamp":1770761323656,"version":"3.50.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12902-017-0194-2","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T22:26:21Z","timestamp":1499984781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss"],"prefix":"10.1186","volume":"17","author":[{"given":"Alison J.","family":"Dawson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Coady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer M. M.","family":"Elshewehy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssra","family":"Dakroury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen L.","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thozhukat","family":"Sathyapalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,14]]},"reference":[{"issue":"7","key":"194_CR1","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.4049\/jimmunol.1403205","volume":"195","author":"P Mai","year":"2015","unstructured":"Mai P, et al. Endocannabinoid system contributes to liver injury and inflammation by activation of bone marrow-derived Monocytes\/macrophages in a CB1-dependent manner. J Immunol. 2015;195(7):3390\u2013401.","journal-title":"J Immunol"},{"issue":"5","key":"194_CR2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/hep.27686","volume":"61","author":"B Mukhopadhyay","year":"2015","unstructured":"Mukhopadhyay B, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology. 2015;61(5):1615\u201326.","journal-title":"Hepatology"},{"issue":"5","key":"194_CR3","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","volume":"115","author":"D Osei-Hyiaman","year":"2005","unstructured":"Osei-Hyiaman D, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5):1298\u2013305.","journal-title":"J Clin Invest"},{"issue":"3","key":"194_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmet.2007.12.007","volume":"7","author":"WI Jeong","year":"2008","unstructured":"Jeong WI, et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab. 2008;7(3):227\u201335.","journal-title":"Cell Metab"},{"key":"194_CR5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1476-511X-13-173","volume":"13","author":"D Shi","year":"2014","unstructured":"Shi D, et al. Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model. Lipids Health Dis. 2014;13:173.","journal-title":"Lipids Health Dis"},{"issue":"26","key":"194_CR6","doi-asserted-by":"crossref","first-page":"8351","DOI":"10.3748\/wjg.v20.i26.8351","volume":"20","author":"E Vassilatou","year":"2014","unstructured":"Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol. 2014;20(26):8351\u201363.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"194_CR7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00592-009-0148-x","volume":"47","author":"C Oberlinner","year":"2010","unstructured":"Oberlinner C, et al. Alanine-aminotransferase levels predict impaired glucose tolerance in a worksite population. Acta Diabetol. 2010;47(2):161\u20135.","journal-title":"Acta Diabetol"},{"issue":"6","key":"194_CR8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0015-0282(00)00501-X","volume":"73","author":"B Kolodziejczyk","year":"2000","unstructured":"Kolodziejczyk B, et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000;73(6):1149\u201354.","journal-title":"Fertil Steril"},{"issue":"4","key":"194_CR9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1665-2681(19)31902-7","volume":"6","author":"A Duseja","year":"2007","unstructured":"Duseja A, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol. 2007;6(4):222\u20136.","journal-title":"Ann Hepatol"},{"issue":"2","key":"194_CR10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2265.2008.03309.x","volume":"70","author":"LW Cho","year":"2009","unstructured":"Cho LW, et al. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol. 2009;70(2):233\u20137.","journal-title":"Clin Endocrinol"},{"issue":"22","key":"194_CR11","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297\u2013307.","journal-title":"N Engl J Med"},{"issue":"6","key":"194_CR12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2265.2008.03260.x","volume":"69","author":"T Sathyapalan","year":"2008","unstructured":"Sathyapalan T, et al. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clin Endocrinol. 2008;69(6):931\u20135.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"194_CR13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","volume":"4","author":"S Zelber-Sagi","year":"2006","unstructured":"Zelber-Sagi S, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4(5):639\u201344.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"194_CR14","doi-asserted-by":"crossref","unstructured":"Moher D, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):e1\u201337.","DOI":"10.1016\/j.jclinepi.2010.03.004"},{"key":"194_CR15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2015.10.006","volume":"77","author":"M Dirchwolf","year":"2015","unstructured":"Dirchwolf M, et al. Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity. Cytokine. 2015;77:14\u201325.","journal-title":"Cytokine"},{"issue":"1","key":"194_CR16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2001.25540","volume":"121","author":"JB Dixon","year":"2001","unstructured":"Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91\u2013100.","journal-title":"Gastroenterology"},{"issue":"10","key":"194_CR17","first-page":"661","volume":"8","author":"N Alkhouri","year":"2012","unstructured":"Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8(10):661\u20138.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"17","key":"194_CR18","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/sim.4780131703","volume":"13","author":"S Senn","year":"1994","unstructured":"Senn S. Testing for baseline balance in clinical trials. Stat Med. 1994;13(17):1715\u201326.","journal-title":"Stat Med"},{"issue":"2","key":"194_CR19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/acel.12438","volume":"15","author":"C Lipina","year":"2016","unstructured":"Lipina C, et al. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction. Aging Cell. 2016;15(2):325\u201335.","journal-title":"Aging Cell"},{"key":"194_CR20","doi-asserted-by":"crossref","unstructured":"Chen MJ, Ho HN. Hepatic manifestations of women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:119\u201328.","DOI":"10.1016\/j.bpobgyn.2016.03.003"},{"issue":"10","key":"194_CR21","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.111.039412","volume":"39","author":"MA Bergstrom","year":"2011","unstructured":"Bergstrom MA, et al. Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant. Drug Metab Dispos. 2011;39(10):1823\u201332.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"194_CR22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1152\/ajpgi.00456.2007","volume":"294","author":"SV Siegmund","year":"2008","unstructured":"Siegmund SV, Schwabe RF. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2008;294(2):257\u201362.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"194_CR23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1152\/ajpgi.00467.2007","volume":"294","author":"A Mallat","year":"2008","unstructured":"Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):9\u201312.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"194_CR24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/1319-3767.114505","volume":"19","author":"KA Alswat","year":"2013","unstructured":"Alswat KA. The role of endocannabinoids system in fatty liver disease and therapeutic potentials. Saudi J Gastroenterol. 2013;19(4):144\u201351.","journal-title":"Saudi J Gastroenterol"},{"issue":"3","key":"194_CR25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/ATVBAHA.108.176362","volume":"29","author":"JP Despres","year":"2009","unstructured":"Despres JP, et al. Effect of rimonabant on the high-triglyceride\/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-lipids trial. Arterioscler Thromb Vasc Biol. 2009;29(3):416\u201323.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"194_CR26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ijo.2012.116","volume":"37","author":"R Bergholm","year":"2013","unstructured":"Bergholm R, et al. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans. Int J Obes. 2013;37(5):699\u2013703.","journal-title":"Int J Obes"},{"issue":"4","key":"194_CR27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2337\/db09-1482","volume":"59","author":"T Jourdan","year":"2010","unstructured":"Jourdan T, et al. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes. 2010;59(4):926\u201334.","journal-title":"Diabetes"},{"issue":"1","key":"194_CR28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.21641","volume":"46","author":"M Gary-Bobo","year":"2007","unstructured":"Gary-Bobo M, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa\/fa rats. Hepatology. 2007;46(1):122\u20139.","journal-title":"Hepatology"},{"issue":"7","key":"194_CR29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"FX Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7):761\u201375.","journal-title":"JAMA"},{"issue":"9468","key":"194_CR30","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Gaal Van","year":"2005","unstructured":"Van Gaal LF, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389\u201397.","journal-title":"Lancet"},{"issue":"9548","key":"194_CR31","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"AJ Scheen","year":"2006","unstructured":"Scheen AJ, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368(9548):1660\u201372.","journal-title":"Lancet"},{"issue":"11","key":"194_CR32","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.2337\/diabetes.53.11.2855","volume":"53","author":"N Sattar","year":"2004","unstructured":"Sattar N, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes. 2004;53(11):2855\u201360.","journal-title":"Diabetes"},{"issue":"4","key":"194_CR33","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1210\/jcem.87.4.8404","volume":"87","author":"V Jayagopal","year":"2002","unstructured":"Jayagopal V, et al. The biological variation of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 2002;87(4):1560\u20132.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-017-0194-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:50:30Z","timestamp":1569804630000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-017-0194-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,14]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["194"],"URL":"https:\/\/doi.org\/10.1186\/s12902-017-0194-2","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,14]]},"article-number":"41"}}